<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="131161">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01900977</url>
  </required_header>
  <id_info>
    <org_study_id>HPTN 071</org_study_id>
    <secondary_id>11865</secondary_id>
    <nct_id>NCT01900977</nct_id>
  </id_info>
  <brief_title>Population Effects of Antiretroviral Therapy to Reduce HIV Transmission (PopART)</brief_title>
  <acronym>PopART</acronym>
  <official_title>Population Effects of Antiretroviral Therapy to Reduce HIV Transmission (PopART): A Cluster-randomized Trial of the Impact of a Combination Prevention Package on Population-level HIV Incidence in Zambia and South Africa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HIV Prevention Trials Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Office of the U.S. Global AIDS Coordinator</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bill and Melinda Gates Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>London School of Hygiene and Tropical Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zambart</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Desmond Tutu HIV Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>HIV Prevention Trials Network</source>
  <oversight_info>
    <authority>United Kingdom: Research Ethics Committee, London School of Hygiene and Tropical Medicine</authority>
    <authority>South Africa: Human Research Ethics Committee, Stellenbosch University</authority>
    <authority>Zambia: Research Ethics Committee, University of Zambia</authority>
    <authority>U.S.: Centers for Disease Control and Prevention</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      PopART is a community randomized trial that is investigating whether a community-wide
      combination HIV prevention package including annual home-based HIV testing, active referral
      and the offer of immediate ART for those testing HIV-positive, along with the promotion of
      proven HIV prevention methods (such as voluntary medical male circumcision, prevention of
      mother to child transmission and condom use), will help to prevent transmission and
      substantially reduce new HIV infections. The study is being conducted in 21 communities in
      Zambia and South Africa (randomized into 3 arms, each with 7 communities) with a total
      population of approximately 1.2 million individuals.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HIV Prevention Trials Network (HPTN) 071 (PopART) will investigate the impact on HIV
      incidence of universal voluntary HIV counseling and testing (with referral to care) provided
      to a community through a house-to-house campaign, in combination with early ART for
      individuals who are HIV-positive, and other proven preventive interventions. The design of
      HPTN 071 (PopART) will allow the study team to distinguish between the impact of universal
      testing with referral for HIV care in accordance with national guidelines, and the impact of
      universal testing with referral for early ART initiation for those with HIV infection. In
      addition, HPTN 071 (PopART) will determine if a program of universal voluntary testing,
      including early ART initiation, is feasible and acceptable when delivered on a large scale
      to entire communities. Evaluating the effectiveness of universal voluntary HIV counseling
      and testing with the offer of early ART is a key global health priority.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">April 2017</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>HIV incidence in members of the Population Cohort (PC) over three years of follow-up</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>HIV incidence over the first, second, and third years of follow-up</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ART adherence and viral suppression</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>HIV viral load at 24 months in HIV-infected members of the Population Cohort who initiated HIV care and ART after commencement of the PopART intervention in the community (if funding available)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Herpes Simplex Virus -2 (HSV-2) incidence</measure>
    <time_frame>12 months, 24 months, and 36 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Incident HSV-2 infections at 12 months, 24 months, and 36 months for all individuals in the Population Cohort who were HSV-2-uninfected at enrollment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV disease progression, retention in care, and death</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ART toxicity</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>ART safety and clinical events among Population Cohort participants initiating ART after commencement of the PopART intervention in the community, measured using routine health center data, and
ART safety and clinical events among health center attendees who  initiated ART after commencement of the PopART intervention in the community, measured using routine health center data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sexual risk behavior</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>o Self-reported sexual risk behavior at Enrollment, 12 months, 24 months, and 36 months in the Population Cohort</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Case notification rate of tuberculosis (TB)</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Case notification rates of bacteriologically-confirmed TB diagnosed among the general population of patients seeking care at health centers as recorded by health centers
TB mortality among TB cases in the community as recorded by health centers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV-related stigma</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Self-reported data on stigma indicators at enrollment, 12 months, 24 months, and 36 months in the Population Cohort
Qualitative interviews in selected members of the general population in Arms A, B, and</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uptake of PMTCT</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Self-reported use of services for PMTCT at Enrollment, 12 months, 24 months, and 36 months among HIV-infected women in the Population Cohort who had been pregnant in the prior 12 months
Uptake of PMTCT services at health centers
Uptake of PMTCT as indicated in data collected in households by CHiPs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uptake of male circumcision</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Self-reported circumcision status/uptake at Enrollment, 12 months, 24 months, and 36 months of men in the Population Cohort
Uptake of circumcision in the community as indicated in health center data
Uptake of circumcision as indicated in data collected in households by CHiPs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ART screening and uptake</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>The proportion of Population Cohort members, identified as HIV-infected who screen for ART eligibility, and who subsequently initiate ART
Proportion of community members, identified as HIV-infected in data from CHiP teams, who screen for ART eligibility, and who subsequently initiate ART, as indicated in health center data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV testing and retesting</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Self-reported recent HIV testing at Enrollment, 12 months, 24 months, and 36 months in the Population Cohort
The number of adults (16 years and older) in the household and the number of HIV tests performed as indicated in data from CHiP teams and health centers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time between HIV diagnosis and initiation of care</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>The proportion of Population Cohort members initiating HIV care within 3 months of a positive HIV diagnosis
The proportion of community members initiating HIV care within 3 months of HIV diagnosis as indicated in data from CHiP teams (provision of HIV positive result) and health center data (date of care initiation)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">52500</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Arm A Universal Testing w/Immediate ART</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B ART according to National Guidelines</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Includes:
Strengthening of HIV testing and ART services according to national guidelines at health facilities and other venues; Strengthening of male circumcision and PMTCT services available at health facilities and other venues in the community; and Treatment of STIs and provision of condoms at health facilities and other venues in the community.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Universal Testing with immediate ART</intervention_name>
    <description>â€¢ Combination prevention package including:
o House-to-house deployment of: Universal HIV counseling and testing; Active linkage to care for individuals diagnosed as HIV-infected, with immediate eligibility for ART; Promotion of male circumcision and prevention of mother to child transmission (PMTCT) services; Provision of condoms; Strengthening of HIV testing and services at health facilities and other venues; Strengthening of male circumcision and prevention of mother-to-child transmission of HIV services available in the community; and Treatment of sexually transmitted infections (STIs) and provision of condoms at health units</description>
    <arm_group_label>Arm A Universal Testing w/Immediate ART</arm_group_label>
    <other_name>PopART Intervention</other_name>
    <other_name>UTT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Universal Testing with ART eligibility according to National Guidelines</intervention_name>
    <description>Combination prevention package including:
House-to-house deployment of: Universal HIV counseling and testing; Active linkage to care for individuals diagnosed as HIV-infected, with ART eligibility according to national guidelines; Promotion of male circumcision and PMTCT services; Provision of condoms; Strengthening of HIV testing and services at health facilities and other venues; Strengthening of male circumcision and PMTCT services available in the community; and Treatment of STIs and provision of condoms at health units.</description>
    <arm_group_label>Arm B ART according to National Guidelines</arm_group_label>
    <other_name>PopART Intervention</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of Care</intervention_name>
    <arm_group_label>Standard of Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Population Cohort

               1. 18 - 44 years of age

               2. Able and willing to provide informed consent

               3. Residing within catchment area of a designated local health unit and intending
                  to remain so for the next three years

               4. Residing in a randomly selected household

          2. Case-Control Study 1 Inclusion Criteria:

               1. At least 18 years of age

               2. Able and willing to provide informed consent

               3. Resident in the cluster during the first round of testing

               4. Visited by a CHiP team and offered testing during the first round of home-based
                  testing

          3. Case-Control Study 2 Inclusion Criteria:

               1. At least 18 years of age

               2. Able and willing to provide informed consent

               3. Resident in the cluster during the first round of testing

               4. Tested HIV-infected in CHiP home-based testing, or HIV-infected and disclosed
                  that they were previously diagnosed as HIV-infected to CHiP team

          4. Case-Control Study 3 Inclusion Criteria:

               1. At least 18 years of age

               2. Able and willing to provide informed consent

               3. Resident in the cluster during the second round of testing

               4. Visited by a CHiP team and offered testing during the second round of home-based
                  testing

        Exclusion Criteria:

          1. Population Cohort Exclusion Criteria:

               1. Current or planned enrollment in another HIV treatment, prevention, or
                  Pre-Exposure Prophylaxis (PrEP) study

               2. Current, planned or prior enrollment in an HIV vaccine study

               3. Anything that, in the opinion of the investigator, would preclude informed
                  consent, make study participation unsafe, complicate interpretation of study
                  outcome data, or otherwise interfere with achieving the study objectives.

          2. Case-Control Study 1 Exclusion Criteria:

               1. Individuals belonging to the Population Cohort or other case-control studies

               2. Individuals known to be HIV-infected after testing elsewhere.

          3. Case-Control Study 2 Exclusion Criteria:

               1. Individuals enrolled in the Population Cohort or other case-control studies

               2. HIV-infected individuals already on ART before study commences

          4. Case-Control Study 3 Exclusion Criteria:

               1. Known HIV infected from CHiP data.

               2. Individuals belonging to the Population Cohort or other case-control studies
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>44 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Hayes, BSc, MSc, DSc</last_name>
    <role>Study Chair</role>
    <affiliation>London School of Hygiene and Tropical Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sarah Fidler, MBBS, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Helen Ayles, BSc, MBBS,  MSc, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>London School of Hygiene and Tropical Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nulda Beyers, MBChB, FCP, MSc, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stellenbosch Univeristy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sam Griffith</last_name>
    <phone>919.544.7040</phone>
    <phone_ext>11571</phone_ext>
    <email>sgriffith@fhi360.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ayana Moore, PhD</last_name>
    <phone>919.544.7040</phone>
    <phone_ext>11244</phone_ext>
    <email>amoore@fhi360.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Desmund Tutu TB Centre at Stellenbosch University</name>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <zip>7505</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nulda Beyers, MD</last_name>
      <phone>27 21 938 9114</phone>
      <email>nb@sun.ac.za</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zambart</name>
      <address>
        <city>Lusaka</city>
        <country>Zambia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helen Ayles, MD</last_name>
      <phone>260 211 254 710</phone>
      <email>helen@zambart.org.zm</email>
    </contact>
  </location>
  <location_countries>
    <country>South Africa</country>
    <country>Zambia</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 3, 2014</lastchanged_date>
  <firstreceived_date>July 2, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Universal Test and Treat (UTT)</keyword>
  <keyword>Combination Prevention</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
